Standout Papers

Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection 2002 2026 2010 2018 511
  1. Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection (2002)
    Sharon Walmsley, Barry Bernstein et al. New England Journal of Medicine
  2. GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease (2018)
    Rohit Loomba, Zeid Kayali et al. Gastroenterology
  3. Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial (2021)
    Stephen A. Harrison, Peter Ruane et al. Nature Medicine
  4. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection (2022)
    Sorana Segal‐Maurer, Edwin DeJesus et al. New England Journal of Medicine

Immediate Impact

1 by Nobel laureates 19 from Science/Nature 65 standout
Sub-graph 1 of 18

Citing Papers

Efruxifermin in Compensated Liver Cirrhosis Caused by MASH
2025 Standout
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
2024 Standout
4 intermediate papers

Works of Peter Ruane being referenced

Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
2021 Standout
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease
2018 Standout
and 1 more

Author Peers

Author Last Decade Papers Cites
Peter Ruane 3291 2152 1628 77 4.6k
Kees Brinkman 3750 2281 1697 136 5.9k
Daniel Vittecoq 1848 1142 1146 141 3.5k
Adrian S. Ray 4346 1639 1953 108 7.1k
Marc van der Valk 2538 1845 1599 210 4.5k
Mauro Moroni 2386 1975 1293 165 6.6k
Pierre‐Marie Girard 3570 2822 2704 241 7.0k
Graeme Moyle 4770 3732 1448 214 6.7k
Eugenia Quirós-Roldán 1953 1094 1019 223 4.1k
Markus Flepp 4070 2728 2021 75 5.5k
Andrew Cheng 6118 4156 1674 94 7.3k

All Works

Loading papers...

Rankless by CCL
2026